T2 Biosystems (NASDAQ:TTOO), which entered 2015 with seven direct sales reps, plans to add another eight during the year as it continues to roll out its first products: the T2Candida panel and T2Dx instrument for the detection of Candida fungal infections that cause sepsis. John McDonough “Our focus is on closing 30 accounts this year within the top 450 hospitals in the U.S. that treat sepsis,” John McDonough, president and CEO, says in an interview with BioTuesdays.com.
Sepsis is one of the leading causes of death in the U.S., with a 30% mortality rate, of which Candida infections are the most lethal with a 40% mortality rate.
Help employers find you! Check out all the jobs and post your resume.
